3.9 C
Sunday, April 21, 2024
NewsChallenge: Targeted Genome Editor Delivery (TARGETED)

Challenge: Targeted Genome Editor Delivery (TARGETED)

DISCLAIMER: Information and opinions reproduced in the articles are the ones of those stating them and it is their own responsibility. Publication in The European Times does not automatically means endorsement of the view, but the right to express it.

DISCLAIMER TRANSLATIONS: All articles in this site are published in English. The translated versions are done through an automated process known as neural translations. If in doubt, always refer to the original article. Thank you for understanding.

The European Times News aims to cover news that matter to increase the awareness of citizens all around geographical Europe.

Recent advancements in the genome editing technology field have enabled scientists to manipulate genomic sequences rapidly and efficiently. Despite revolutionary progress in this area, several challenges remain. Existing gene editing technologies like CRISPR-cas9, base editors and prime editors have great potential. Still, existing delivery technologies cannot deliver gene editing technologies to many target tissues and cell types in sufficient quantities, which hinders clinical applications. While some cell types, like hepatocytes in the liver, have many delivery technologies capable of delivering genome editors, many other organs and cell types are harder to reach.

The Challenge is a three-phase competition:

In Phase 1, Participants will be asked to submit a proposal describing their proposed solution and how it will address the requirements for one of the Target Areas. Participants may submit proposed solutions to both Target Areas but must do so with separate proposals that independently address each Target Area’s requirements. Up to ten proposals judged to meet the best requirements will each be awarded up to $75,000. Additional prizes of $50,000 may be awarded to additional meritorious solutions based on the Judging Criteria.

In Phase 2, Participants must submit data from studies that demonstrate delivery and editing performance and describe their methodology, technology, and how their solution addresses the Challenge criteria. Participation in Phase 1 is not a requirement for participation in Phase 2; however, it is strongly encouraged. Up to 10 winners of Phase 2 will be each awarded $250,000 and will be eligible to compete in Phase 3. Only Phase 2 winners will be eligible to participate in Phase 3.

Phase 3 is separated into Phase 3a and Phase 3b; all participants must submit solutions for Phase 3a to be eligible to participate in Phase 3b. For Phase 3a, Participants must submit all required information showing that their technology is ready for large animal testing through NIH-supported independent evaluation and can solve the requirements for one of the Target Areas.

Submissions to this Challenge must be received by  12:00 AM EET, January 11, 2025.

Source: Challenge.gov

Source link

- Advertisement -

More from the author

- Advertisement -
- Advertisement -
- Advertisement -spot_img
- Advertisement -

Must read

Latest articles

- Advertisement -